Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 7 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 10899826

    Pharmaceutical compositions for an anti-CGRP antagonist antibody

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted

  2. WO 2021005494

    ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIALES POUR LE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES ET NEUROLOGIQUES

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 14, 2021 · Expires Jan 9, 2041

    granted

  3. WO 2021005497

    ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIUM POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA DÉPRESSION CORTICALE ENVAHISSANTE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 14, 2021 · Expires Jan 9, 2041

    granted

  4. WO 2021005493

    ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 14, 2021 · Expires Jan 9, 2041

    granted

  5. US 10888601

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 12, 2021 · Expires Jan 7, 2041

    granted

  6. US 10881660

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted

  7. US 10864217

    Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Dec 15, 2020 · Expires Dec 10, 2040

    granted

  8. US 10857205

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted

  9. US 10857231

    Formulations of VEG antagonist fusion proteins and method of manufacturing them

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted

  10. US 10849908

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted

  11. US 10836744

    Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted

  12. US 10828345

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted

  13. US 10780095

    Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists

    The Regents of the University of California · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  14. US 10774128

    IL-33 antagonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  15. US 10766877

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted

  16. US 10745394

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

  17. US 10745397

    1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

  18. US 10716770

    Nicotinic receptor non-competitive antagonists

    Catalyst Biosciences, Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  19. US 10689373

    1,2-substituted cyclopentanes as orexin receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  20. US 10683277

    Triazole derivatives as P2Y14 receptor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted

  21. US 10676469

    Kappa opioid receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  22. US 10653743

    Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N

    Arizona Board of Regents on Behalf of the University of Arizona · Granted May 19, 2020 · Expires May 14, 2040

    granted

  23. US 10654842

    Dopamine D3 receptor antagonist compounds

    Indivior UK Limited · Granted May 19, 2020 · Expires May 14, 2040

    granted

  24. US 10624850

    Emulsion formulations of an NK-1 receptor antagonist and uses thereof

    Heron Therapeutics, Inc. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.